Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Healthcare-focused Baker Bros. Advisors’ Top Picks: Incyte, Alexion, ACADIA & More

Baker Bros. Advisors is a New York City-based fund launched in 2000 by Julian and Felix Baker. The firm focuses on life science and biotechnology companies, and recently has disclosed an equity portfolio valued at more than $12.07 billion as of December 31.  During the fourth quarter, the fund’s 35 long positions in companies with market caps above $1.0 billion delivered weighted average returns of 9.4%, according to our calculations. For the full 2015, these long holdings posted a weighted average return of 6.7%. In this article, we’ll take a look at Baker Bros.’ top picks heading into 2016.

Out of thousands of stocks that are trading on the market every day, it can be difficult sometimes to pick the right investment that can deliver market-beating returns. By analyzing the equity portfolios of 700+ top investors, we can see what stocks they are collectively bullish on and use this data to compile a portfolio that can outperform the market. We have determined through this process that the best strategy is to follow the 15 most popular small-cap picks among hedge funds (see more details).

#5. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

– Shares Owned by Baker Bros. as of December 31: 20.48 Million

– Value of Holding as of December 31: $730.16 Million

Follow Acadia Pharmaceuticals Inc (NASDAQ:ACAD)
Trade (NASDAQ:ACAD) Now!

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) kept the fifth spot in Baker Bros.’ list as the stake  remained unchanged over the October-to-December period, but the value rose considerably, as the stock gained 7.8% over the quarter. On January 8, however, the fund declared it had increased its exposure to 23.11 million shares. This stake makes it the largest institutional investor of record in the company; also bullish on ACADIA seems to be Ken Griffin’s Citadel Investment Group, which last disclosed ownership of 1.12 million shares.

Shares of ACADIA have lost more than 47 percent year-to-date, amid the announcement of an underwritten public offering of $300,000,000 of shares of its common stock, the appointment of a new Board Director, and a decline in the wider biotech segment. The company is scheduled to announce its fourth quarter and full year 2015 financial results before the market opens next Monday and analysts expect a loss of $0.38 per share on revenue worth $60,000.

#4. AbbVie Inc (NYSE:ABBV)

– Shares Owned by Baker Bros. as of December 31: 14.37 Million

– Value of Holding as of December 31: $851.58 Million

Follow Abbvie Inc. (NYSE:ABBV)
Trade (NYSE:ABBV) Now!

The value of Baker Bros’ position in AbbVie Inc (NYSE:ABBV) rose, as the stock gained 8.88% during the fourth quarter. Nonetheless, the company witnessed the hedge fund support decrease over the period, with the number of funds in our database long the stock having dropped to 70. AbbVie’s shares have tumbled since the beginning of the year, but the losses were not as large and the stock is down by about 6.5% year-to-date. On Tuesday, Citi’s Andrew Baum upgraded his rating on AbbVie to ‘Buy’ from ‘Neutral’, but boosted the price target to $65 from $56, arguing that the market is underestimating the potential of the company’s Humira drug.

On the next page we will take a look at Baker Bros.’ top three picks held as of the end of the fourth quarter of 2015.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.